Community Practice

Latest News


CME Content


Changes to formularies continue to be among the most frustrating aspects of the Medicare prescription drug benefit for pharmacists and physicians, and most confusing to beneficiaries.

Ambrisentan (Letairis) from Gilead Sciences, Inc. has been approved by the FDA for patients with PAH (WHO Group 1) with WHO Functional Class II or III symptoms.

Patient takes tramadol 100 mg every six hours for chronic back pain; other medications include two lithium carbonate, extended release tablets, ziprasidone, temazepam, and trazodone.

Researchers at the American Society of Clinical Oncology meeting stressed that treatment more targeted, with fewer side effects, than before - and cancer deaths are down for the first time in 70 years.

Walgreen Co. has reached an agreement to purchase specialty pharmacy operator Option Care Inc. for about $850 million. Option Care, based in Buffalo Grove, Ill., provides a full spectrum of specialty-pharmacy and home-infusion services

According to CMS, its partner Argus Health Systems will begin building a network of pharmacies and the program will work similarly to third-party insurance?providing pharmacists with specific instructions on how to handle prescriptions for victims of disasters.